Slide 1: Oriola Corporation Interim report January-September 2022
Oriola Corporation Interim report January-September 2022
Slide 2: Q3 2022 key points
Q3 2022 key points “Solid performance continued despite the inflationary environment” • Total Oriola net sales +3.3% and invoicing +1.3%. Comparable adjusted EBIT increased to EUR 13.5m (10.4) • Continuing operations net sales +4.1% (on a constant currency basis +6.9%) and adjusted EBIT increased to
Slide 3: Key figures Q1-Q3 2022 for continuing and discontinued operations
Key figures Q1-Q3 2022 for continuing and discontinued operations Invoicing Q1-Q3 Net sales Q1-Q3 Adjusted EBIT Q1-Q31 EUR million EUR million EUR million 3 500 1 500 55 50 3 000 45 1 200 481 466 16.5 2 500 982 439 40 970 429 917 915 370 35 844 900 2 000 30 25 13,5 504 1 500 1 019 436 468 17,1 942 8
Slide 4: Operating environment
Operating environment A S-, \
Slide 5: Oriola Services markets were growing in Q3
Oriola Services markets were growing in Q3 Market share wholesale Market share dose dispensing Sweden Sweden Pharmaceutical market in value Q3: Total market 52 BSEK Oriola 45% (46%) Oriola 30% (43%) Sweden +6.6% ~ 260,000 Others 55% (54%) patients Others 70% (57%) Source: IQVIA and Oriola estimate S
Slide 6: Pharmacy market value and volume grew in Q3 in Sweden
Pharmacy market value and volume grew in Q3 in Sweden Pharmacy market value development in Sweden in Q3: +5.7% Pharmacy market volume grew in Sweden in Q3 Online pharmacy market size in Sweden Total online pharmacy market grew by 9% in Market shares in Q3 Pharmacy 397 market in Q3 BSEK Jul-Sep 2022
Slide 7: Segment reviews Q3 2022
Segment reviews Q3 2022
Slide 8: Oriola Services Q3: Higher demand, turnaround initiatives offsetting cost pressures
Continuing operations Oriola Services Q3: Higher demand, turnaround initiatives offsetting cost pressures • Market demand growing in Sweden and Finland Adjusted EBIT 1 EUR million 2020 2021 2022 • Invoicing increased by 1.4% to EUR 870.6m, (on a constant currency basis +4.1%) 10 8,7 8,7 • Net sales
Slide 9: Consumer Q3: Growth in online sales, cost pressures mitigated
Discontinued operations Consumer Q3: Growth in online sales, cost pressures mitigated • Growing market demand in local currency Adjusted EBIT 1 • Net sales decreased by 3.2% to EUR 193.9m, (on a EUR million 2020 2021 2022 constant currency basis +0.9%), driven by 16 Consumer, impact of lower depreci
Slide 10: Financials Q3 2022
Financials Q3 2022 i
Slide 11: Q3: Profit for the period and EPS increased
Continuing and discontinued operations Q3: Profit for the period and EPS increased Profit for the period, continuing and Earnings per share, continuing and discontinued operations discontinued operations EUR million EUR 2020 2021 2022 2020 2021 2022 16 0.09 14.6 0.08 14 0.08 12,0 0,07 12 0.06 10 8.8
Slide 12: Strong year-to-date cash flow
Continuing and discontinued operations Strong year-to-date cash flow Quarterly net cash flow from operating activities1 Q3 YTD 2022 change in cash1 EUR million EUR million 2020 2021 2022 80 200 60 46 42 150 39 -3.5 40 29 28 41,8 -8.1 20 100 9 4 0 139,3 0 50 109,1 -20 -14 -16 -26 -40 0 Q1 Q2 Q3 Q4 Ca
Slide 13: Q3: Net debt declined Y/Y, driven by increased cash flow and improved result
Q3: Net debt declined Y/Y, driven by increased cash flow and improved result Net interest-bearing debt1 Net interest-bearing debt items EUR million EUR million 2020 2021 2022 160 Net interest-bearing debt item 30 Sep 2022 30 Sep 20211 140 Bank loans 61.6 65.5 (syndicated Bank & term) 120 Commercial
Slide 14: Equity ratio and gearing improved in Q3 2022
Equity ratio and gearing improved in Q3 2022 Equity ratio1 Gearing2 % % 2020 2021 2022 2020 2021 2022 25 125 21,8 102,3 20,1 99,8 20 19.1 19,8 19,9 100 91.8 94.7 18.0 75,0 75 14,8 64.1 15 14.1 14.0 13.3 53,8 12,4 46.5 50 10 25 15.5 8,3 5 0 -4,6 0 -25 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 1 Includes discontinued o
Slide 15: Outlook for 2022
Outlook for 2022 (published on 3 October 2022) The adjusted EBIT for the continuing operations is estimated to increase from the 2021 level. The new outlook is based on Oriola’s continuing operations. The COVID-19 pandemic continues and severity as well as duration of the pandemic remain unclear in
Slide 16: Turnaround continues
Turnaround continues
Slide 17: Short-term action plan to improve profitability during 2022
Short-term action plan to improve profitability during 2022 – impacts fully visible in 2023 1. Cost savings • All the initiatives related to EUR 7 million cost savings target have been implemented New in 2022 in both continuing and discontinued operations operating model • Divestment of pharmacy sta
Slide 18: Estimated impact of the joint venture transaction
Estimated impact of the joint venture transaction • There will be a one-time negative impact of the transaction, amounting to approximately EUR 30 million in Q4/2022. • Non-current assets are not depreciated, while they are classified as held for sale. This had a positive impact of EUR 16.5 million
Slide 19: Q3 2022 Key take-aways
Q3 2022 Key take-aways “Solid performance continued despite the inflationary environment” 1 Net sales and invoicing in continuing operations continued to increase – adjusted EBIT EUR 6.6m, +23% 2 Own efficiency and cost saving measures continued to mitigate inflation 3 Turnaround activities progress
Slide 20: Our next events Thank you!
Our next events 30/11/2022 Investor Day 16/2/2023 Financial Statements Release 2022 Contact: investor.relations@oriola.com Thank you!
Slide 21: 27.10.2022
27.10.2022 21